Baidu
map

Blood:MPN患者动脉血栓栓塞提示继发癌症

2019-12-26 不详 MedSci原创

中心点:在本病例对照研究中,MPN继发癌症患者的血栓栓塞发生率高于匹配的无癌的MPN患者。动脉血栓栓塞的发生于癌症风险增加2倍相关。摘要:费城染色体阴性的骨髓增殖性肿瘤(MPN)患者容易继发癌症,但其相关因素尚未明确。Stefano等人开展一项国际性的病例对照研究,招募了647位癌症患者、127位非黑色素瘤皮肤癌患者、62位MPN合并血液继发癌症患者、32位MPN合并黑色素瘤患者。此外,还纳入12

中心点:

在本病例对照研究中,MPN继发癌症患者的血栓栓塞发生率高于匹配的无癌的MPN患者。

动脉血栓栓塞的发生于癌症风险增加2倍相关。

摘要:

费城染色体阴性的骨髓增殖性肿瘤(MPN)患者容易继发癌症,但其相关因素尚未明确。

Stefano等人开展一项国际性的病例对照研究,招募了647位癌症患者、127位非黑色素瘤皮肤癌患者、62位MPN合并血液继发癌症患者、32位MPN合并黑色素瘤患者。此外,还纳入1234位无癌症病史的性别、年龄匹配的MPN患者。在MPN类型、驱动突变暴露和心血管危险因素等方面,病例组与对照组相当。

病例组和对照组在确诊MPN之前的血栓发生率相近(19.8% vs 21.2%)。在确诊MPN后、继发癌症前,病例组的血栓事件多于对照组(11.6% vs 8.1%),主要是动脉血栓栓塞的比例增加(6.2% vs 3.7%)。经多个混杂因素校正后,动脉血栓栓塞与癌症风险仍独立相关,提示确诊MPN后,患者如发生动脉血栓栓塞事件,则需进行密切的临床监测,以早期发现癌症。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1935497, encodeId=e538193549e65, content=<a href='/topic/show?id=4302121e605' target=_blank style='color:#2F92EE;'>#MPN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12176, encryptionId=4302121e605, topicName=MPN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 16 12:45:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724507, encodeId=87961e24507de, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Jan 25 12:45:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709012, encodeId=a22f1e09012c3, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Jul 13 01:45:00 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536825, encodeId=7f4a153682527, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Sat Dec 28 01:45:00 CST 2019, time=2019-12-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1935497, encodeId=e538193549e65, content=<a href='/topic/show?id=4302121e605' target=_blank style='color:#2F92EE;'>#MPN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12176, encryptionId=4302121e605, topicName=MPN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 16 12:45:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724507, encodeId=87961e24507de, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Jan 25 12:45:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709012, encodeId=a22f1e09012c3, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Jul 13 01:45:00 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536825, encodeId=7f4a153682527, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Sat Dec 28 01:45:00 CST 2019, time=2019-12-28, status=1, ipAttribution=)]
    2020-01-25 feifers
  3. [GetPortalCommentsPageByObjectIdResponse(id=1935497, encodeId=e538193549e65, content=<a href='/topic/show?id=4302121e605' target=_blank style='color:#2F92EE;'>#MPN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12176, encryptionId=4302121e605, topicName=MPN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 16 12:45:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724507, encodeId=87961e24507de, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Jan 25 12:45:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709012, encodeId=a22f1e09012c3, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Jul 13 01:45:00 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536825, encodeId=7f4a153682527, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Sat Dec 28 01:45:00 CST 2019, time=2019-12-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1935497, encodeId=e538193549e65, content=<a href='/topic/show?id=4302121e605' target=_blank style='color:#2F92EE;'>#MPN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12176, encryptionId=4302121e605, topicName=MPN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Feb 16 12:45:00 CST 2020, time=2020-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1724507, encodeId=87961e24507de, content=<a href='/topic/show?id=78ece8958b2' target=_blank style='color:#2F92EE;'>#继发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78958, encryptionId=78ece8958b2, topicName=继发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=499d33645837, createdName=feifers, createdTime=Sat Jan 25 12:45:00 CST 2020, time=2020-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1709012, encodeId=a22f1e09012c3, content=<a href='/topic/show?id=1502333250f' target=_blank style='color:#2F92EE;'>#动脉血#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33325, encryptionId=1502333250f, topicName=动脉血)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=048f31575940, createdName=ms9833124466084992, createdTime=Mon Jul 13 01:45:00 CST 2020, time=2020-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1536825, encodeId=7f4a153682527, content=<a href='/topic/show?id=fcbd3332949' target=_blank style='color:#2F92EE;'>#动脉血栓#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33329, encryptionId=fcbd3332949, topicName=动脉血栓)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=715e12724163, createdName=yangcx0919, createdTime=Sat Dec 28 01:45:00 CST 2019, time=2019-12-28, status=1, ipAttribution=)]

相关资讯

Blood:JAK2 V617F和CALR突变的人群发生率和表现

JAK2 V617F和calrenetin突变(CALR)是骨髓增生性肿瘤(MPN)中常见的驱动突变。在普通人群中可检测到JAK2 V617F,但尚无研究调查CALR的发生率。Sabrina Cordua等人开展研究来明确CALR和JAK2 V617F的人群发生率,同时评估有携带这两个突变的MPN患者和非MPN患者的生化特征和生活方式风险因素。2010年-2013年,共招募了19 958位受试者,

Blood:JAK2突变型造血细胞的代谢变化可作为MPN的治疗靶点

能量需求增多和代谢重编程是癌细胞的特征。Tata Nageswara Rao等人发现造血细胞的代谢改变是JAK2突变驱动骨髓增生性肿瘤(MPNs)发病的机制基础。研究人员还发现突变体JAK2的表达增强并破坏了MPN细胞的代谢活性,导致体内的系统代谢改变,包括低血糖、脂肪组织萎缩和早期死亡。在MPN小鼠模型中,低血糖与高活性红细胞生成有关,这是由于糖酵解和氧化磷酸化增强共同作用的结果。通过高脂饮食调

Blood:在骨髓增生性肿瘤中,突变型钙网蛋白与MPL之间的致病性的相互作用。

钙网蛋白(CALR)突变是骨髓增生性肿瘤(MPN)的发病机制中的表型驱动因素。机械论学说已证实突变的CALR与血小板生成素受体MPL结合,突变型CALR介导激活JAK-STAT信号通路需要突变型CALR C末端的正电荷。研究人员发现,虽然突变型CALR和MPL结合对于突变型CALR转化造血细胞是必需的,但只有该结合对细胞因子独立生长又是不够的。突变型CALR C末端的正电荷的阈值会影响突变CALR

Blood:NFE2突变可促进AML特异性遗传突变的获得

中心点:AML患者的转录因子NFE2常发生突变。在小鼠中,NFE2突变可诱导MPN,随后转化成AML,并获得AML特异性的遗传变异。摘要:在急性髓系白血病(AML)中,获得性遗传变异具有预后意义,并可指导治疗决策的制定。目前临床算法已纳入了新发突变。Jonas Samuel Jutzi等人发现AML患者和髓肉瘤患者携带转录因子NFE2突变,并对其功能特征进行研究。研究人员既往在骨髓增殖性肿瘤患者中

Blood:单细胞技术发现了驱动恶性造血干细胞自我更新的分子网络

中心点:单细胞技术可鉴别恶性HSC自我更新的调控子。摘要:单细胞技术的最新进展使得我们可以既往不能达到的分辨率来研究异质性细胞群。Mairi S. Shepherd等人利用该技术探究驱动小鼠造血干细胞(HSCs)疾病的分子机制,以JAK2V617F突变型骨髓及髓外增殖性肿瘤(MPNs)为模型。单细胞基因表达和功能分析发现了一个JAK2V617F突变型HSCs的亚集,表现为自我更新缺陷。该缺陷可在单

Blood:Jak2V617F协同Dnmt3a缺失通过激活增强子驱动的炎症信号诱导骨髓纤维化

中心点:造血干细胞丢失Dbnt3a协同Jak2V617F可诱导致死性的骨髓纤维化。Dnmt3a缺失导致增强子激活,驱动异常的自我更新和炎症信号。摘要:骨髓增生性肿瘤(MPN)是在造血干细胞和祖细胞(HSPC)发生遗传病变后发生的一组血液癌症。Sebastien Jacquelin等人发现Jak2V617F表达和Dnmt3a缺失之间的突变协同作用可驱动早期真性红细胞增多症进展至晚期骨髓纤维化。通过C

Baidu
map
Baidu
map
Baidu
map